Your session is about to expire
← Back to Search
Nivolumab + Ipilimumab for Pituitary Cancer
Study Summary
This trial will test if nivolumab and ipilimumab can help people with pituitary tumors that have worsened after surgery and radiation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Women of childbearing potential must have a negative pregnancy test when they join the study.I have a tumor in my pituitary gland.Your blood test results must meet certain standards.I am 18 years old or older.You have a disease that can be measured using specific criteria.My cancer has grown after radiation treatment.My tumor can't be removed surgically and is likely a pituitary adenoma, as per scans or tests.It's been over 4 weeks since my last temozolomide dose and I've recovered from other chemotherapy effects.I am a man who will use contraception during and after the study, unless I am sterile or cannot produce sperm.I am able to care for myself but may not be able to do active work.You have had a strong allergic reaction to any monoclonal antibody in the past.I cannot have imaging tests for monitoring my condition.I am not pregnant or breast-feeding.I have not been treated with CTLA-4 antibodies but may have had PD1 or PD-L1 therapy without serious side effects.I do not have a history of hepatitis B or C infection.I have a pituitary carcinoma and radiotherapy is not considered beneficial for me.I take more than 4mg of dexamethasone daily.You have had a known autoimmune disease within the past 2 years that is currently active or suspected.
- Group 1: Pituitary Cancer
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what capacity is Nivolumab typically utilized?
"Nivolumab is a common remedy for conditions that have not responded to anti-angiogenic therapy. It has also been used successfully to address malignant neoplasms, unresectable melanoma, and squamous cell carcinoma."
To what extent is this medical research project being implemented in various hospitals across the state?
"8 facilities are presently enrolling individuals for this trial, situated in Uniondale, Middletown and Commack alongside other nearby locations. Therefore, it is recommended to select a site closest to you in order to reduce your need of travelling if participating."
Have researchers previously investigated the efficacy of Nivolumab?
"Currently, Nivolumab is the subject of 765 active clinical studies with 86 in their last stage. While Pittsburgh, Pennsylvania serves as a hub for these trials, 42755 medical sites are conducting research on this medication worldwide."
What is the current magnitude of subjects receiving treatment in this experiment?
"21 individuals who meet the prerequisites of this trial need to be recruited. Potential participants can join from Memorial Sloan Kettering Nassau (Limited Protocol Activities) in Uniondale, New york and Memoral Sloan Kettering Monmouth (Limited Protocol Activities) in Middletown, New jersey."
To what extent can Nivolumab be detrimental to patient health?
"The safety of Nivolumab is rated as a 2, since the Phase 2 trial has presented evidence in favour of its security but not its efficacy."
Are there any open vacancies for this clinical trial?
"According to clinicaltrials.gov, this research endeavour is actively seeking the participation of patients; it was initially posted on July 31st 2019 and amended in October 2021."
Share this study with friends
Copy Link
Messenger